Determination of Irsogladine Using HPLC-ESI-MS/MS in Human Plasma: Application to Bioequivalence Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nguyen Huu Hoang | - |
dc.contributor.author | Nguyen Lan Huong | - |
dc.contributor.author | Hong, Sung-Yong | - |
dc.contributor.author | Park, Je Won | - |
dc.date.accessioned | 2021-09-04T05:27:13Z | - |
dc.date.available | 2021-09-04T05:27:13Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0326-2383 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/90355 | - |
dc.description.abstract | A highly sensitive analytical tool for the fast quantification of irsogladine in human plasma was developed. Cleanup using a solid-phase extraction technique is a simple method for extracting both irsogladine and lamotrigine (internal standard) spiked into human plasma: 89.4 +/- 2.4% for irsogladine and 85.9 +/- 3.4% for lamotrigine. The resolvable separation of both analytes through reversed-phase high-performance liquid chromatography (HPLC) was carried out within 5 min. The HPLC-electrospray ionization (ESI)-tandem mass spectrometry (MS) method, which was operated in a selected reaction monitoring mode specific to the target analytes, was verified for use in the quantification of irsogladine. The inter-and intra-day precision (RSD) were < 4% and their accuracies were between 85.9 to 89.8%. The calibration curve for irsogladine spiked into human plasma was linear over the range from 1 to 100 ng/mL; the limit of quantification was estimated to be 1.8 ng/mL. The established method was successfully applied for a bioequivalence study of irsogladine. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES | - |
dc.subject | MALEATE | - |
dc.title | Determination of Irsogladine Using HPLC-ESI-MS/MS in Human Plasma: Application to Bioequivalence Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Je Won | - |
dc.identifier.scopusid | 2-s2.0-84986903250 | - |
dc.identifier.wosid | 000388287200029 | - |
dc.identifier.bibliographicCitation | LATIN AMERICAN JOURNAL OF PHARMACY, v.35, no.8, pp.1894 - 1898 | - |
dc.relation.isPartOf | LATIN AMERICAN JOURNAL OF PHARMACY | - |
dc.citation.title | LATIN AMERICAN JOURNAL OF PHARMACY | - |
dc.citation.volume | 35 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1894 | - |
dc.citation.endPage | 1898 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | MALEATE | - |
dc.subject.keywordAuthor | bioequivalence study | - |
dc.subject.keywordAuthor | HPLC-ESI-MS/MS | - |
dc.subject.keywordAuthor | human plasma | - |
dc.subject.keywordAuthor | irsogladine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.